Current status of inhaled nitric oxide therapy for lung transplantation in Japan: a nationwide survey

Yoshiyasu, Nobuyuki; Sato, Masaaki; Nakajima, Daisuke; Tomioka, Yasuaki; Watanabe, Yui; Shiraishi, Takeshi; Funaki, Soichiro; Maeda, Shin; Tomoshige, Koichi; Nakajima, Takahiro; Tsuchiya, Tomoshi; Sugimoto, Seiichiro; Yoshino, Ichiro; Nagayasu, Takeshi; Chida, Masayuki; Minami, Masato; Okada, Yoshinori; Toyooka, Shinichi; Date, Hiroshi; Nakajima, Jun

doi:10.1007/s11748-021-01648-8

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of iNO in heart transplant recipients leads to a decrease in pulmonary artery pressure and improvements in hemodynamic parameters, but does not affect long-term survival [ 255 , 256 ]. There is also little evidence to support the long-term benefit of iNO in lung transplant patients; however, some professional communities rate the efficacy of iNO as reasonable and recommend public health insurance for inhaled NO therapy during lung transplant [ 257 ]. The therapeutic potential of iNO, combined with a good safety profile, justifies its use despite the lack of definitive evidence to support improved long-term outcomes or survival among cardiac surgery patients, heart transplant patients, lung transplant patients and patients undergoing LVAD implantation [ 258 ].…”

Section: Translation Of the Effects Of Nitric Oxide Into Clinical Pra...mentioning

confidence: 99%

Nitric Oxide in Cardiac Surgery: A Review Article

Каменщиков

Duong

2023

Biomedicines

View full text Add to dashboard Cite

Perioperative organ injury remains a medical, social and economic problem in cardiac surgery. Patients with postoperative organ dysfunction have increases in morbidity, length of stay, long-term mortality, treatment costs and rehabilitation time. Currently, there are no pharmaceutical technologies or non-pharmacological interventions that can mitigate the continuum of multiple organ dysfunction and improve the outcomes of cardiac surgery. It is essential to identify agents that trigger or mediate an organ-protective phenotype during cardiac surgery. The authors highlight nitric oxide (NO) ability to act as an agent for perioperative protection of organs and tissues, especially in the heart–kidney axis. NO has been delivered in clinical practice at an acceptable cost, and the side effects of its use are known, predictable, reversible and relatively rare. This review presents basic data, physiological research and literature on the clinical application of NO in cardiac surgery. Results support the use of NO as a safe and promising approach in perioperative patient management. Further clinical research is required to define the role of NO as an adjunct therapy that can improve outcomes in cardiac surgery. Clinicians also have to identify cohorts of responders for perioperative NO therapy and the optimal modes for this technology.

show abstract

Section: Translation Of the Effects Of Nitric Oxide Into Clinical Pra...mentioning

confidence: 99%

Nitric Oxide in Cardiac Surgery: A Review Article

Каменщиков

Duong

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Typical dosages are 10–20–40 ppm. Intraoperatively, iNO is used in 98% and postoperatively in 90%, of lung transplant cases [ 72 ]. The background is a dual effect of iNO.…”

Section: Strategymentioning

confidence: 99%

“…However, the occurrence in adults is rare overall (<3%). Especially in lung transplantation, there was no higher incidence of renal failure observed [ 72 , 76 ]. Studies on the effect of iNO on RI showed contradictory results, so that overall, neither clinically nor currently a clear recommendation for or against iNO can be given on the basis of the available data [ 14 , 75 ].…”

Section: Strategymentioning

confidence: 99%

Intraoperative Circulatory Support in Lung Transplantation: Current Trend and Its Evidence

Starke

Dossow

Karsten

2022

Life

View full text Add to dashboard Cite

Lung transplantation has a high risk of haemodynamic complications in a highly vulnerable patient population. The effects on the cardiovascular system of the various underlying end-stage lung diseases also contribute to this risk. Following a literature review and based on our own experience, this review article summarises the current trends and their evidence for intraoperative circulatory support in lung transplantation. Identifiable and partly modifiable risk factors are mentioned and corresponding strategies for treatment are discussed. The approach of first identifying risk factors and then developing an adjusted strategy is presented as the ERSAS (early risk stratification and strategy) concept. Typical haemodynamic complications discussed here include right ventricular failure, diastolic dysfunction caused by left ventricular deconditioning, and reperfusion injury to the transplanted lung. Pre- and intra-operatively detectable risk factors for the occurrence of haemodynamic complications are rare, and the therapeutic strategies applied differ considerably between centres. However, all the mentioned risk factors and treatment strategies can be integrated into clinical treatment algorithms and can influence patient outcome in terms of both mortality and morbidity.

show abstract